Fortress Biotech, Inc.
FBIO
$2.76
$0.072.60%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -5.13% | -10.21% | -13.50% | -12.80% | 1.78% |
| Total Other Revenue | -84.16% | -87.52% | -94.86% | -94.88% | 3,268.79% |
| Total Revenue | -23.56% | -28.23% | -32.11% | -31.76% | 31.51% |
| Cost of Revenue | -49.76% | -48.14% | -53.25% | -41.59% | -48.88% |
| Gross Profit | 1,006.88% | 217.48% | 115.88% | 60.28% | 102.16% |
| SG&A Expenses | 36.23% | 42.65% | 13.94% | -4.45% | -22.69% |
| Depreciation & Amortization | 6.57% | 18.02% | 33.53% | 55.72% | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -9.69% | -8.75% | -26.37% | -27.20% | -36.22% |
| Operating Income | -4.22% | -8.76% | 22.07% | 24.37% | 57.94% |
| Income Before Tax | 56.55% | 16.90% | 22.83% | 21.60% | 32.38% |
| Income Tax Expenses | -19.20% | -22.12% | -22.12% | -22.12% | -24.07% |
| Earnings from Continuing Operations | 56.42% | 16.92% | 22.83% | 21.60% | 32.36% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -22.92% | 11.60% | -21.74% | -19.95% | -28.08% |
| Net Income | 108.22% | 63.80% | 24.49% | 24.14% | 38.05% |
| EBIT | -4.22% | -8.76% | 22.07% | 24.37% | 57.94% |
| EBITDA | -4.34% | -9.62% | 22.40% | 24.32% | 58.82% |
| EPS Basic | 93.86% | 70.25% | 64.92% | 68.11% | 72.11% |
| Normalized Basic EPS | -47.98% | 155.81% | 173.54% | 156.97% | 152.67% |
| EPS Diluted | 91.86% | 69.02% | 64.89% | 68.09% | 72.10% |
| Normalized Diluted EPS | -54.76% | 152.96% | 173.54% | 156.97% | 152.67% |
| Average Basic Shares Outstanding | 61.70% | 84.37% | 111.50% | 150.40% | 137.88% |
| Average Diluted Shares Outstanding | 75.05% | 89.85% | 111.50% | 150.40% | 137.88% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | 1.00% | 1.00% | 0.67% | 0.34% | -0.21% |